A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)

A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)

Brief description of study

Primary FSGS is a progressive disease that causes the kidneys to scar, to leak protein into the urine and may lead to kidney failure. This study is being done to see whether a new medication, called CXA-10, can reduce the amount of protein in the urine and maintain stable kidney function in patients with primary FSGS. CXA-10 is an investigational medication which means it has not yet been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary FSGS. The pharmaceutical company sponsoring this study is Complexa, inc.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    FSGS,Primary Focal Segmental Glomerulosclerosis,
  • Age: Between 18 Years - 100 Years
  • Gender: All


Updated on 29 Sep 2022. Study ID: 831546

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center